T-regulatory Cells in Diabetic Type Two Nephropathy

Status Not yet recruiting

Clinical Trial Summary

Diabetes mellitus is one of the most prevalent health problems worldwide. Diabetic nephropathy has become the leading cause of end-stage kidney disease worldwide and is associated with an increased cardiovascular risk.

Traditionally, metabolic and hemodynamic factors are the main causes of renal lesions in patients with type two diabetes mellitus and diabetic nephropathy , both considered non-immune diseases. Serial researches has demonstrated that diabetic nephropathy is a metabolic and hemodynamic disorder, with inflammation playing a vital role in the process.

Clinical Trial Description

It has been reported that glomerular basement membranes from diabetic rats induced significantly greater amounts of Tumor necrotic factor-alpha and Interleukin-1 than when these cells were incubated with basement membranes from non-diabetic rats.

These new findings were the first to suggest that inflammatory cytokines may participate in the pathogenesis of diabetic nephropathy .Cluster of differentiation 4 cells are believed to play central roles in modulating immune responses. Tumor necrotic factor-alpha and Interleukin-6, and induce inflammation in the pathogenesis of autoimmune diseases.

T- regulatory cells exert immunosuppressive effects which are important on the maintenance of immune homeostasis by producing anti-inflammatory cytokines, such as Interleukin-10 and transforming growth factor-b.

Aim of this work is to the role of T regulatory cells :( Cluster of differentiation 4, Cluster of differentiation 25,Cluster of differentiation 127 , forkhead box P3 cells) in the different stages of diabetic nephropathy before hemodialysis initiation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03591939
Study type	Observational
Source	Assiut University
Contact	Muhammed Hossam Maghraby, professor
Phone	00201020671222
Email	hossammaghraby@med.au.edu.eg
Status	Not yet recruiting
Phase
Start date	August 1, 2018
Completion date	October 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Completed	`NCT04549324` - Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Recruiting	`NCT03502031` - Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy	Phase 4
Completed	`NCT03681704` - the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD	Phase 1
Completed	`NCT03681249` - the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD	Early Phase 1
Withdrawn	`NCT03504566` - Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)	Phase 4
Completed	`NCT03889236` - Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.	N/A
Completed	`NCT06326034` - Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients	Phase 4
Recruiting	`NCT04931537` - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Not yet recruiting	`NCT05373004` - Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease	Phase 2/Phase 3
Recruiting	`NCT03622762` - Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy	Phase 2
Recruiting	`NCT03445247` - Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy	N/A
Not yet recruiting	`NCT06068439` - Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy	Phase 2/Phase 3
Recruiting	`NCT04143412` - Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination	Phase 2
Not yet recruiting	`NCT06222476` - Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.	N/A
Completed	`NCT05487755` - Investigational and Comparative Study in the Management of Diabetic Nephropathy	Phase 3
Active, not recruiting	`NCT04573920` - Atrasentan in Patients With Proteinuric Glomerular Diseases	Phase 2
Recruiting	`NCT05888909` - Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Not yet recruiting	`NCT04962399` - Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
Active, not recruiting	`NCT03859817` - Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient